COVID-19 / Coronavirus

Amway launches Singapore Business Innovation Hub to accelerate health and wellness innovation

2022-12-08 09:30 1324

Hub launched in partnership with the Economic Development Board to serve as a springboard for product innovation to meet consumers' evolving wellness needs globally and also uniquely inAsia, backed by science and technology SINGAPORE, Dec. 8, 2022 /PRNewswire/ -- Amway, an entrepreneur-led health...

BSR KOREA Introduces "Wizbiosolutions Inc." as "2022 Global Procurement Marketer"

2022-12-08 00:00 1508

SEOUL, South Korea, Dec. 7, 2022 /PRNewswire/ -- As the practitioner of "2022 Global Procurement Marketer (GPM) Project" promoted by the Ministry of SMEs and Startups (MSS) and Korea SMEs and Startups Agency (KOSME), BSR KOREA offered consultation for 40 domestic SMEs that want to enter the inter...

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA

2022-12-07 18:10 1334

--The objective of Phase I clinical trial is to identify a safe and efficacious dose for the pivotal Phase II/III in COVID-19 patients. Phase I clinical trial is expected to be completed within the first quarter of 2023 --Phase I clinical trial will also determine if ASC11 needs to be boosted by ...

Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)

2022-12-06 21:01 1581

* Akeso Inc. to out-license to Summit Therapeutics exclusive rights to ivonescimab (PD-1/VEGF) for the development and commercialization inthe United States, Canada, Europe, and Japan. Akeso Inc. will retain development and commercialization rights for the rest of the world includingChina. * ...

University of Tokyo and Sekisui House Launch Joint Research on Biodiversity and Health

2022-12-06 14:00 1096

TOKYO, Dec. 6, 2022  /PRNewswire/ -- - World's First Research into Relationship between Rich-in-Biodiversity Garden Greenery and Health/Well-being - The University of Tokyo's Graduate School of Agricultural and Life Sciences (GSALS) and Sekisui House, Ltd. launched a joint research project on b...

University of Tokyo and Sekisui House Launch Joint Research on Biodiversity and Health

2022-12-06 14:00 977

- World's First Research into Relationship between Rich-in-Biodiversity Garden Greenery and Health/Well-being - TOKYO, Dec. 6, 2022 /PRNewswire/ -- The University of Tokyo's Graduate School of Agricultural and Life Sciences (GSALS) and Sekisui House, Ltd. launched a joint research project on bio...

Zhongchao Inc. Established SID Liver Cancer Comprehensive-Disciplinary Physician Education Platform

2022-12-05 20:30 972

SHANGHAI, Dec. 5, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that after three years of preparation, the Company's MDMOOC platf...

Lakeshore Acquisition Corp I Shareholders Approve Business Combination with ProSomnus

2022-12-03 05:05 3166

SAN FRANCISCO, Dec. 2, 2022 /PRNewswire/ -- Lakeshore Acquisition I Corp. (Nasdaq: LAAA) ("Lakeshore") today announced that its shareholders have approved all proposals related to the previously announced business combination (the "Business Combination") with ProSomnus Holdings, Inc. ("ProSomnus"...

HAVAS HEALTH & YOU EXPANDS CONTENT EXPERTISE THROUGH PARTNERSHIP WITH EVERMED

2022-12-01 22:15 1516

NEW YORK, Dec. 1, 2022 /PRNewswire/ -- COVID-19 dramatically changed the way doctors interact with the health industry – they're looking for more convenient and efficient ways to consume medical information than ever, leading to an uptick in demand for content. To help address the need for more c...

BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine

2022-12-01 21:00 2265

VANCOUVER, BC, Dec. 1, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce the successful sterile and bacteria-free test-run production of BVX-0918, the Company's bi-haptenized autologous ovarian cancer vaccine.   ...

Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met

2022-12-01 19:30 752

SUZHOU, China, Dec. 1, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("KintorPharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced results of phase II clinical trial of pyrilutamide (KX-826), a poten...

Dr Ivan Puah Shares 5 Beauty & Body Sculpting Trends In The Cosmetic & Aesthetic Industry For 2023

2022-12-01 08:00 1101

SINGAPORE, Dec. 1, 2022 /PRNewswire/ -- As we look forward to the new year, Dr Ivan Puah, Medical Director at Amaris B. Clinic, who has more than 15 years of medical aesthetics and surgical body contouring experience, shares five beauty and body sculpting trends expected to take centre stage in 2...

Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index

2022-11-30 22:15 2130

LONDON and HONG KONG, Nov. 30, 2022 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced that its board of directors has authorized a share repurchase program, and that it has been included as a c...

Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne

2022-11-30 20:41 1111

--To date, approximately 50% enrolled patients have completed 12-week treatment and all enrolled patients are expected to complete 12-week treatment by the end ofFebruary 2023 -- Clinical efficacy observed in patients who have completed 12-week treatment of ASC40 or placebo was comparable t...

Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne

2022-11-30 20:39 802

--To date, approximately 50% enrolled patients have completed 12-week treatment and all enrolled patients are expected to complete 12-week treatment by the end ofFebruary 2023 -- Clinical efficacy observed in patients who have completed 12-week treatment of ASC40 or placebo was comparable t...

Navigating a perfect storm - driving access to healthcare in emerging markets

2022-11-30 15:00 936

* Healthcare demand and expenditure in Southeast Asia are set to increase rapidly amidst rising affluence and an ageing population * Emerging markets comprise 60% of the global population but contribute only 20% of global healthcare spending, highlighting the issue of equitable access * An i...

Infinitus co-organizes the 2022 Responsibilities for Health Forum

2022-11-30 08:00 1504

The firm releases the National TCM Health Index Report 2022 at the forum GUANGZHOU, China, Nov. 30, 2022 /PRNewswire/ -- Organized by the Office of the National Brands Project of Xinhua News Agency, co-organized by Infinitus with the support of the China Association of Chinese Medicine (CACM), th...

AROA BIOSURGERY ANNOUNCES HALF YEAR RESULTS

2022-11-29 13:24 1580

AUCKLAND, New Zealand, Nov. 29, 2022 /PRNewswire/ -- Today New Zealand based soft-tissue regeneration company Aroa Biosurgery (AROA, the Company) is pleased to announce financial results for H1 FY23.  With fewer COVID-19 related disruptions, the Company has entered FY23 with momentum and delivere...

BGI Genomics, Naleya Genomics Indonesia, MGI, and Bumame contribute aid packages to Cianjur earthquake relief efforts

2022-11-29 08:38 1788

CIANJUR, Indonesia, Nov. 29, 2022 /PRNewswire/ -- A 5.6-magnitude earthquake struck the Cianjur district,West Java last Monday (Nov. 21, 2022). As part of earthquake relief efforts, BGI Genomics, its subsidiary Naleya Genomics Indonesia (NGI) and MGI are partnering withIndonesia's leading healthc...

Ascletis Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA

2022-11-29 08:10 2692

HANGZHOU, China and SHAOXING, China, Nov. 29, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that the Investigational New Drug (IND) application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease (3CLpro) for COVID-19, has been ac...

12345 ... 202